Polio vaccination regimen shift to IPV followed by OPV instead of OPV alone debated at IoM/CDC conference.
POLIO IMMUNIZATION WITH INACTIVATED AND LIVE VACCINES SHOULD REPLACE OPV, Samuel Katz, MD, Duke University, said at a June 8 Institute of Medicine/Centers for Disease Control & Prevention workshop on polio vaccines in Washington, D.C. In arguing for the change, Katz cited the estimated eight to 10 annual U.S. cases of vaccine-associated paralytic polio (VAPP) in people who have taken oral polio vaccine, and the three-year absence of the wild strain of polio from the Western hemisphere. "We have to show that we accept the fact that in a polio-free nation in a polio-free hemisphere we cannot have eight to 10 individuals paralyzed every year when there are alternatives," Katz said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth